Report Highlights
The global market for microRNA (miRNA) research tools, services, diagnostics and drug discovery was valued at $478.8 million in 2013. This market is expected to reach $572 million in 2014 and $1 billion in 2019, at a compound annual growth rate (CAGR) of 12.6% for the period of 2014 to 2019.
Report Includes
- An overview of the global market for microRNA diagnostics and therapeutics with an analysis of the commercial potential of this research field.
- Analyses of global market trends, with data from 2013, estimates for 2014, and projections of CAGRs through 2019.
- Examination of the extensive portfolio of miRNA pathway drug candidates, some already in Phase II clinical trials, showing promising clinical data in different areas of medicine, such as cancer, HCV infection, and cardiovascular diseases.
- A focus on recent drug candidates, products, deals between different pharmaceutical companies, major participants, and new trends and developments.
- Identification of the main markets for RNA therapeutics.
Report Scope
This BCC Research report is a business tool that is intended to help biotechnology companies evaluate emerging commercial opportunities in the microRNA reagent, diagnostic and therapeutic submarkets. The existing leading players in this market segment are provided with an opportunity to learn what the other competitors in this nascent arena have achieved to gain a stronger foothold in the sector in their quest for bringing to the market blockbuster therapeutics to treat diseases with significant unmet medical needs.
Analyst Credentials
P. Natana Raj is a medical analyst and has edited 25 market research reports in the past nine years, covering pharmaceuticals, medical devices, stem cells, regenerative medicine and beverages. He is a retired college professor with 32 years of experience in teaching biochemistry, biotechnology, biochemical pharmacology, molecular biology and genetics. In addition to his Master of Science degree in Biology, he also holds diplomas in biochemistry, biochemical pharmacology, biotechnology and environmental biology.
Report Highlights
The global microRNA research tools market was valued at nearly $295.1 million in 2011 and should reach nearly $338.3 million in 2012. Total market value is expected to reach $763 million in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 17.7%.
Report Includes
- An overview of the global market for microRNA diagnostics and therapeutics with an analysis of the commercial potential of this research field
- Analyses of global market trends, with data from 2011, estimates for 2012, and projections of compound annual growth rates (CAGRs) through 2017
- Examination of the extensive portfolio of miRNA pathway drug candidates, some already in Phase II clinical trials, showing promising clinical data in different areas of medicine, such as cancer, HCV infection, and cardiovascular diseases
- A focus on recent drug candidates, products, deals between different pharmaceutical companies, major participants, and new trends and developments during the last two years
- Forecasts of the future situation and major drawbacks of the miRNA drug development model and possible solutions for these obstacles, especially in context of drug stability and delivery
- Identification of the main markets for RNA therapeutics
- Comprehensive company profiles of major players in the industry.
Related Reports
RNAi Drug Delivery: Technologies and Global Markets
The global market for RNAi drug delivery technologies reached nearly $9.3 billion in 2012 and nearly $11.7 billion in 2013. This market is expected to grow to $38.8 billion in 2018, with a compound annual growth rate(CAGR) of 27.2% from 2013 to 2018.
DNA Sequencing: Emerging Technologies and Applications
The global market for sequencing products and services reached $3.5 billion in 2012. This market is expected to grow to nearly $4.5 billion in 2013 and nearly 11.7 billion in 2018, a compound annual growth rate (CAGR) of 21.2%.
Global Biochip Markets: Microarrays and Lab-on-a-Chip
The global biochip products market reached $3.3 billion in 2012. This market is expected to grow to nearly $3.9 billion in 2013 and $14.4 billion in 2018 at a compound annual growth rate (CAGR) of 30% for the five-year period 2013 to 2018.
Molecular Diagnostics: Technologies and Global Markets
In 2012, the global DNA diagnostics market was valued at $17.3 billion. The total market is projected to reach $20.1 billion in 2013 and nearly $36.5 billion by 2018, increasing at a compound annual growth rate (CAGR) of 12.6% from 2013 through 2018.
Recent Reports
Bioprocess Optimization and Digital Bio-manufacturing: Global Markets
The global market for bioprocess optimization and digital biomanufacturing is expected to grow from $24.3 billion in 2024 and is projected to reach $39.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.2% during the forecast period of 2024 to 2029.
Global DNA Sequencing: Research, Applied and Clinical Markets
The global market for DNA sequencing is expected to grow from $14.8 billion in 2024 and is projected to reach $34.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 18.6% during the forecast period of 2024 to 2029.
Artificial Intelligence (AI) in Cancer
The global market for artificial intelligence (AI) in cancer is estimated to increase from $2.2 billion in 2024 to reach $6.3 billion by 2029, at a compound annual growth rate (CAGR) of 23.1% from 2024 through 2029.
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.
Single-use Technologies for Biopharmaceuticals: Global Markets
The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.
Top Trending Reports
Single-use Technologies for Biopharmaceuticals: Global Markets
The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.
Medical Devices Industry: Competitive Landscape
The global market for medical devices is estimated to increase from 810.4 billion in 2024 to reach $1.3 trillion by 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.
Global Market Opportunities and Competitive Landscape for CDMO
The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.
Chronic Disease Management: Therapeutics, Device Technologies and Global Markets
The global market for chronic disease management therapeutics and device technologies was valued at $675.0 billion in 2023. It is projected to grow from $726.3 billion in 2024 to $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 8.1% from 2024 through 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More